key: cord-0879132-459o88ib authors: Méndez, Raúl; Latorre, Ana; González-Jiménez, Paula; Feced, Laura; Bouzas, Leyre; Yépez, Katheryn; Ferrando, Ana; Zaldívar-Olmeda, Enrique; Reyes, Soledad; Menéndez, Rosario title: Reduced Diffusion Capacity in COVID-19 Survivors date: 2021-03-30 journal: Annals of the American Thoracic Society DOI: 10.1513/annalsats.202011-1452rl sha: 4218d5bbc7b9277a79123169317785ba214816cf doc_id: 879132 cord_uid: 459o88ib nan (75.5%) had a mild alteration (60 to ,80 DL CO %), 13 (24.5%) moderate (40 to ,60 DL CO %), and none severe (,40 DL CO %), respectively. In Table 1 , clinical variables are displayed in relation to altered DL CO . Briefly, in our cohort the patients with altered DL CO were mainly women and had more prevalence of smoking history, higher C-reactive protein and D-dimer concentration during admission, and more severe pneumonia. In the linear regression analysis, female sex, smoking history, and D-dimer levels were associated with lower DL CO values ( ; P 5 0.025). The Spearman correlations between the peak of C-reactive protein and D-dimer levels with DL CO were 20.127 (P 5 0.062) and 20.238 (P , 0.001), respectively. In our study, we found lower prevalence of altered DL CO (24.7%) compared with smaller studies such as Mo and colleagues (47.2%) and Shah and colleagues (52%) but more similar to that reported by Zhao and colleagues (16.4%, 9/55) in a cohort without severe cases (2, 4, 6) . In the first one, PFT was performed before discharge, and in the last one, PFT was performed 3 months after discharge. Our data, together with these others, support the hypothesis that too early a functional assessment is likely to overestimate the chronic impact of disease on DL CO . We found sex differences n DL CO that could be associated with sexspecific airway response to the disease as occurs in women with emphysema, who had thicker small airways (7, 8) . In some studies, impaired DL CO and persistence of symptoms was also more prevalent in women (4, 9) , but these sex differences should be further explored and clarified. Chronic respiratory disease was not associated with worse DL CO values. However, the patients were predominantly asthmatic and the prevalence of chronic obstructive pulmonary disease or interstitial lung diseases was low. On the other hand, smoking history was associated with poorer DL CO , as expected. Finally, maximum D-dimer levels were also associated with lower diffusion capacity. Severe COVID-19 is associated with unspecific diffuse alveolar damage, characterized by edema, hemorrhage, and fibrin deposition (10). In addition, COVID-19 causes relevant vascular changes with characteristics of microangiopathy such as thrombosis, necrosis, or abnormal neoangiogenesis (10) . This fact could be related to poorer DL CO in survivors and should be prospectively evaluated in the long term. Our study has several limitations. This is a single-center study with a limited number of cases, and further studies are needed to validate our findings. In addition, we lack previous functional data preventing its comparison. In any case, the model was adjusted for chronic respiratory disease and smoking history to overcome this limitation. Nonetheless, to the authors' knowledge, this is the largest follow-up study with PFT evaluation in COVID-19. In the last international guidance on the management of COVID-19, 60% of experts were in favor of routine posthospital PFT within 30-60 days regardless of the disease severity (11) . An accurate early identification of patients requiring follow-up PFT is complex and larger studies are needed. Author disclosures are available with the text of this letter at www.atsjournals.org. European Centre for Disease Prevention and Control. COVID-19 situation update worldwide Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery Global Lung Function Initiative TLCO working group; Global Lung Function Initiative (GLI) TLCO. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations National Emphysema Treatment Trial Research Group. Sex differences in severe pulmonary emphysema Considering how biological sex impacts immune responses and COVID-19 outcomes Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study COVID-19: what the clinician should know about post-mortem findings Updated guidance on the management of COVID-19: from an The authors thank Antonio J. Cañada (Data Science, To the Editor:High out-of-pocket costs can be a barrier to asthma controller medication use for children and adults (1) (2) (3) (4) (5) (6) . Families in highdeductible health plans (HDHPs) face annual average deductibles of .$3,000 (7) and must balance the heathcare needs and costs of multiple members. Exempting important services such as medications from the deductible and applying copayments may mitigate these barriers (8) , although deductible costs for other services in HDHPs could strain family budgets and lead to underuse of medications and other health care for some family members in preference to others (9, 10) . We evaluated whether the impact of HDHPs on asthma controller medication use and exacerbations is worse for families with multiple members with asthma. Using a cohort of enrollees aged 4-64 years with commercial coverage in a large national commercial and Medicare Advantage claims database between January 1, 2002, and December 31, 2014, we identified those with $12 months' enrollment in a traditional plan with a low (,$500) or no deductible (baseline) who either were switched by their employer to a plan with an individual deductible of $$1,000 or remained in the traditional plan (controls) for another 12 months (follow-up) among employers who offered only one deductible level per benefit year ( Figure 1 ). An index date separated the baseline and follow-up periods. We directly measured deductible levels when available and otherwise imputed this information using aggregated enrollee out-of-pocket spending within employers (11, 12) . HDHPs required higher cost sharing for specialist, acute care, and emergency department visits than traditional plans; prescription drugs were usually subject to copayments, except for Health Savings Account-eligible HDHPs that subjected all nonpreventive care to the deductible. We included enrollees who met Health Effectiveness Data and Information Set criteria for persistent asthma before baseline (13). We identified enrollees who had another family member in the study population with persistent asthma sharing their insurance plan and selected one enrollee per family.We measured 30-day controller medication fills by identifying all fills for inhaled corticosteroids (ICS), leukotriene inhibitors (LTI), and ICS-long-acting b-agonists (ICS-LABA) in pharmacy claims and used the days' supply recorded for each fill to calculate the number of 30-day fills per enrollee per medication type in each study period. In the follow-up period, we measured the percentage of enrollees whose controller fills were subject to the deductible and the mean copayment per fill for those paying copayments. We measured asthma exacerbations using rates of oral corticosteroid (OCS) bursts, defined as a dispensing of a 3-21 days' supply without a dispensing in the prior 30 days (14).We used a coarsened exact matching approach that balanced employer propensity to switch to offering HDHPs and enrollee-level propensity to work for these employers (Table 1) (11, 12, (15) (16) (17) . We applied match-generated weights in all analyses (12, 15, 17, 18 ). Project Program Award (IHS-1602-34331). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute, its Board of Governors, or its Methodology Committee.